Capivasertib in Combination with Faslodex Granted Priority Review in the US for Patients with Advanced HR-Positive Breast Cancer

12 June 2023 — AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with Faslodex (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor…Original Article